DGKA (diacylglycerol kinase alpha) is a metabolic enzyme that converts diacylglycerol (DAG) into phosphatidic acid (PA), thereby regulating the balance between these two critical lipid second messengers 1. This enzymatic activity positions DGKA as a central switch in cellular signaling pathways with diverse biological effects 1. In cancer contexts, DGKA exhibits dual roles in promoting tumor progression and therapeutic resistance. The enzyme enhances metastasis in non-small cell lung cancer through direct interactions with SRC and FAK proteins, phosphorylating SRC at Tyr416 and FAK at Tyr397 to activate downstream WNT/β-catenin and VEGF signaling pathways that promote epithelial-mesenchymal transition and angiogenesis 2. DGKA also drives platinum resistance in ovarian cancer by activating c-JUN-WEE1 signaling, where its product PA facilitates c-JUN nuclear localization and activation 1. Additionally, DGKA mediates resistance to PD-1 immunotherapy by exacerbating T-cell exhaustion 3. In lung cancer, DGKA promotes tumorigenesis through regulation of cyclin D3 expression 4. These findings establish DGKA as a promising therapeutic target across multiple cancer types, with its inhibition showing potential to overcome various resistance mechanisms and enhance treatment efficacy.